International Journal of Clinical Research

Objective To investigate the clinical efficacy and value of inhalation therapy of terbutaline combined with budesonide in patients with chronic obstructive pulmonary disease (COPD). Methods The number of cases in this study was 200, all of whom were diagnosed and treated with chronic obstructive pulmonary disease (COPD) in our hospital from January 2021 to January 2025. They were randomly divided into a control group and an observation group according to the odd even principle, and treated with single budesonide nebulization therapy and terbutaline combined with budesonide inhalation therapy, respectively. The clinical efficacy, lung function indicators, and blood gas indicators of the two groups of patients were evaluated and analyzed. Results After treatment, the clinical total effective rate, lung function indicators, and blood gas indicators of the observation group were higher, and the incidence of adverse reactions and inflammatory factors were lower. The inter group value P<0.05 indicates the existence of comparative significance. Conclusion The application of Terbutamol combined with Budesonide inhalation therapy in the treatment of patients with chronic obstructive pulmonary disease has significant clinical efficacy, which can effectively improve patients' lung function indicators, blood gas indicators, reduce the occurrence of adverse reactions, and improve patients' quality of life and satisfaction. It is worth promoting in clinical practice.

Tebutalin; Budesonide; Chronic obstructive pulmonary disease; Clinical efficacy